GSK drops commercial duties in Kenya, shifts to distributor model
GSK is shuttering commercial operations in Kenya and tapping third parties to take over distribution, the company said on Thursday morning.
The move, reported earlier by Business Daily Africa, will impact a number of jobs, though GSK has declined to reveal how many. With the spinout of Haleon this summer, GSK no longer owns any manufacturing sites in Kenya.
“We will continue to supply our needed medicines and vaccines in Kenya, and we will work with our distribution partners towards a smooth transition in 2023,” a GSK spokesperson said in an email to Endpoints News.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.